COMMUNIQUÉS West-GlobeNewswire

Causeway Therapeutics Debuts Positive Data from Phase 2 Clinical Trial of TenoMiR® for Lateral Epicondylitis
28/10/2025
Data Show Statistically Significant Improvements in Pain, Function and Tendon Structure in Appropriately Dosed Patients GLASGOW, Scotland, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Causeway Therapeutics , a clinical-stage [...]
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025
28/10/2025
WATERTOWN, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
28/10/2025
NEW HAVEN, Conn., Oct. 28, 2025 (GLOBE NEWSWIRE) -- WHAT: Invivyd, Inc. (Nasdaq: IVVD) is hosting the previously announced live webcast to present an overview of the company’s REVOLUTION clinical program, Invivyd’s [...]
Cronos Brings Back Popular, Limited-Edition Spinach® Green Apple-Flavored Products for the Fall Season
28/10/2025
TORONTO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabinoid company, announced today that it is welcoming back its limited-edition Caramel Green [...]
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
28/10/2025
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated Day 1 and [...]
Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
28/10/2025
Revenue of $189 million, year-over-year increase of 22% as reported and 18% organic with double-digit reported growth across all franchises Orders increased sequentially and greater than 20% year-over-year Increasing [...]
Context Therapeutics to Participate in Upcoming Investor Conferences
28/10/2025
PHILADELPHIA, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid [...]
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
28/10/2025
– ARCALYST ® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth – – ARCALYST 2025 expected net product revenue raised to $670 - $675 million – – KPL-387 granted Orphan [...]
Evidence Against Evidence: CERN-IEEE FPGA vs. Crosetto 3D-Flow, a Breakthrough Invention Recognized 32 Years Ago That Could Have, and Can Still, Save Billions of Euros and Millions of Lives
28/10/2025
Science vs. Consensus: An urgent call to CERN, IEEE, and the scientific community to engage with verifiable evidence, fulfill scientific duty, and resolve contradictions based on the laws of nature, not institutional [...]
BioNTech to Host Innovation Series R&D Day on November 11, 2025
28/10/2025
MAINZ, Germany, October 28 , 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of the Company’s Innovation Series R&D Day at 09:00 a.m. Eastern Standard Time (3: [...]
Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study
28/10/2025
Study met primary and secondary endpoints Paridiprubart demonstrated a relative reduction in the risk of death of 25% Treatment provided patients with clinically meaningful improvement in survival and recovery [...]
SparingVision Doses First Patient with SPVN20 for Advanced Retinitis Pigmentosa in NYRVANA Trial
28/10/2025
SparingVision Doses First Patient with SPVN20 for Advanced Retinitis Pigmentosa in NYRVANA Trial SPVN20 aims to restore visual acuity and aspects of color vision by creating an alternative light-signaling cascade in [...]
Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer
28/10/2025
Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory approvals Dr Smith's appointment will accelerate Step Pharma's ‘pipeline in [...]
Kyowa Kirin and Orchard Therapeutics Announce OTL-200 Granted Orphan Regenerative Medicine Product Designation for Early-onset MLD in Japan
28/10/2025
– First and only disease-modifying therapy for the treatment of eligible children with MLD also receives Orphan Drug Designation and Priority Review in the Kingdom of Saudi Arabia – TOKYO, LONDON and BOSTON, Oct. 28, [...]
Novartis announces expiration of Tourmaline Bio tender offer
28/10/2025
Basel, October 28 2025 - Novartis today announced that its previously announced tender offer (the “offer”) by Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“ [...]
Swarm Oncology announces research collaboration with a leading hospital to advance T cell therapies for advanced solid cancers
28/10/2025
London, United Kingdom October 28, 2025, Swarm Oncology Ltd. (“Swarm Oncology” or “Swarm”), a biotechnology company pioneering novel T cell therapies to achieve long-term remission in patients with advanced solid [...]
Bavarian Nordic Provides Further Support to Mpox Outbreak in Africa through Additional Donation of Vaccines
28/10/2025
COPENHAGEN, Denmark, October 28, 2025 – Bavarian Nordic announced today a donation of mpox vaccines to Africa CDC to support the response to the ongoing mpox outbreak in Africa. The donation of 110,000 doses of the [...]
Présentation du tout premier grand modèle de langage multiomique au monde au salon Global Health Exhibition de Riyad, ou la promesse d’un décodage du langage de la biologie humaine
28/10/2025
Entraîné à partir de données multiomiques, le modèle fondamental de PanOmiQ représente une percée grâce à son déploiement alimenté par des composants logiques programmables (ou FPGA, de l’anglais Field-Programmable Gate [...]
Qualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025
28/10/2025
Dubai, UAE / Beijing, China, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics Inc. (NASDAQ: QLGN) (“Qualigen”, “QLGN” or the “Company”), a publicly-traded technology company majority owned by Faraday Future [...]

Pages